Distinguishing benign from malignant pelvic mass utilizing an algorithm with HE4, menopausal status, and ultrasound findings

被引:44
作者
Wilailak, Sarikapan [1 ]
Chan, Karen K. L. [2 ]
Chen, Chi-An [3 ]
Nam, Joo-Hyun [4 ]
Ochiai, Kazunori [5 ]
Aw, Tar-Choon [6 ]
Sabaratnam, Subathra [7 ]
Hebbar, Sudarshan [8 ]
Sickan, Jaganathan [8 ]
Schodin, Beth A. [8 ]
Charakorn, Chuenkamon [1 ]
Sumpaico, Walfrido W. [9 ]
机构
[1] Mahidol Univ, Ramathibodi Hosp, Fac Med, Dept Obstet & Gynecol, Bangkok 10700, Thailand
[2] Univ Hong Kong, Dept Obstet & Gynecol, Hong Kong, Hong Kong, Peoples R China
[3] Natl Taiwan Univ Hosp, Dept Obstet & Gynecol, Taipei, Taiwan
[4] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Obstet & Gynecol, Seoul, South Korea
[5] Jikei Univ, Dept Obstet & Gynecol, Tokyo, Japan
[6] Changi Gen Hosp, Dept Lab Med, Singapore, Singapore
[7] Hosp Sultanah Aminah, Dept Pathol, Johor Baharu, Johor, Malaysia
[8] Abbott Diagnost, Abbott Pk, IL USA
[9] MCU FDT Med Fdn, Dept Obstet & Gynecol, Caloocan, Philippines
关键词
Algorithms; CA-125; Antigen; Ovarian Neoplasms; Prospective Studies; Regression Analysis; Sensitivity and Specificity; EPITHELIAL OVARIAN-CANCER; EPIDIDYMIS PROTEIN 4; MODEL LR2; RISK; PREDICTION; DIAGNOSIS; MARKER; CA125; WOMEN; COMBINATION;
D O I
10.3802/jgo.2015.26.1.46
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: The purpose of this study was to develop a risk prediction score for distinguishing benign ovarian mass from malignant tumors using CA-125, human epididymis protein 4 (HE4), ultrasound findings, and menopausal status. The risk prediction score was compared to the risk of malignancy index and risk of ovarian malignancy algorithm (ROMA). Methods: This was a prospective, multicenter (n=6) study with patients from six Asian countries. Patients had a pelvic mass upon imaging and were scheduled to undergo surgery. Serum CA-125 and HE4 were measured on preoperative samples, and ultrasound findings were recorded. Regression analysis was performed and a risk prediction model was developed based on the significant factors. A bootstrap technique was applied to assess the validity of the HE4 model. Results: A total of 414 women with a pelvic mass were enrolled in the study, of which 328 had documented ultrasound findings. The risk prediction model that contained HE4, menopausal status, and ultrasound findings exhibited the best performance compared to models with CA-125 alone, or a combination of CA-125 and HE4. This model classified 77.2% of women with ovarian cancer as medium or high risk, and 86% of women with benign disease as very-low, low, or medium-low risk. This model exhibited better sensitivity than ROMA, but ROMA exhibited better specificity. Both models performed better than CA-125 alone. Conclusion: Combining ultrasound with HE4 can improve the sensitivity for detecting ovarian cancer compared to other algorithms.
引用
收藏
页码:46 / 53
页数:8
相关论文
共 26 条
[1]  
[Anonymous], COMMUNITY ONCOL
[2]   Serum Human Epididymis Protein 4 and Risk for Ovarian Malignancy Algorithm as New Diagnostic and Prognostic Tools for Epithelial Ovarian Cancer Management [J].
Bandiera, Elisabetta ;
Romani, Chiara ;
Specchia, Claudia ;
Zanotti, Laura ;
Galli, Claudio ;
Ruggeri, Giuseppina ;
Tognon, Germana ;
Bignotti, Eliana ;
Tassi, Renata A. ;
Odicino, Franco ;
Caimi, Luigi ;
Sartori, Enrico ;
Santin, Alessandro D. ;
Pecorelli, Sergio ;
Ravaggi, Antonella .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2011, 20 (12) :2496-2506
[3]   Adherence to Treatment Guidelines for Ovarian Cancer as a Measure of Quality Care [J].
Bristow, Robert E. ;
Chang, Jenny ;
Ziogas, Argyrios ;
Anton-Culver, Hoda .
OBSTETRICS AND GYNECOLOGY, 2013, 121 (06) :1226-1234
[4]   The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass [J].
Chan, Karen K. L. ;
Chen, Chi-An ;
Nam, Joo-Hyun ;
Ochiai, Kazunori ;
Wilailak, Sarikapan ;
Choon, Aw-Tar ;
Sabaratnam, Subathra ;
Hebbar, Sudarshan ;
Sickan, Jaganathan ;
Schodin, Beth A. ;
Sumpaico, Walfrido W. .
GYNECOLOGIC ONCOLOGY, 2013, 128 (02) :239-244
[5]   Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: A systematic review [J].
du Bois, Andreas ;
Rochon, Justine ;
Pfisterer, Jacobus ;
Hoskins, William J. .
GYNECOLOGIC ONCOLOGY, 2009, 112 (02) :422-436
[6]   Comparison of Serum Human Epididymis Protein 4 with Cancer Antigen 125 as a Tumor Marker in Patients with Malignant and Nonmalignant Diseases [J].
Escudero, Jose M. ;
Auge, Jose M. ;
Filella, Xavier ;
Torne, Aureli ;
Pahisa, Jaume ;
Molina, Rafael .
CLINICAL CHEMISTRY, 2011, 57 (11) :1534-1544
[7]   The Role of HE4 in Ovarian Cancer: Inhibiting Tumour Cell Proliferation and Metastasis [J].
Gao, L. ;
Cheng, H. Y. ;
Dong, L. ;
Ye, X. ;
Liu, Y. N. ;
Chang, X. H. ;
Cheng, Y. X. ;
Chen, J. ;
Ma, R. Q. ;
Cui, H. .
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2011, 39 (05) :1645-1660
[8]  
Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO
[9]  
2-4
[10]   A RISK OF MALIGNANCY INDEX INCORPORATING CA-125, ULTRASOUND AND MENOPAUSAL STATUS FOR THE ACCURATE PREOPERATIVE DIAGNOSIS OF OVARIAN-CANCER [J].
JACOBS, I ;
ORAM, D ;
FAIRBANKS, J ;
TURNER, J ;
FROST, C ;
GRUDZINSKAS, JG .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1990, 97 (10) :922-929